Sagent Pharmaceuticals (SGNT) Prices Up-Sized Offering at $16, High End of Range
Tweet Send to a FriendGet Alerts SGNT Hot Sheet
Up)
Trade SGNT Now!
Sagent Pharmaceuticals (Nasdaq: SGNT) priced an up-sized initial public offering of 5,750,000 shares of common stock at a price to the public of $16.00 per share, the high end of the expected $14-$16 range.
Morgan Stanley, BofA Merrill Lynch, and Jefferies are acting as the joint bookrunners for the offering.
Sagent Pharmaceuticals, founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Morgan Stanley, BofA Merrill Lynch, and Jefferies are acting as the joint bookrunners for the offering.
Sagent Pharmaceuticals, founded in 2006, is a specialty pharmaceutical company focused on developing, manufacturing, sourcing and marketing pharmaceutical products, with a specific emphasis on injectable products.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Maintains Bullish Stance on Walter Energy (WLT)
- Loeb Boosts Sony (SNE) Stake, Continues Urging IPO on Entertainment Unit
- A Sale or an IPO for Nokia Siemens Networks? (NOK)
Create E-mail Alert Related Categories
Hot IPOs, IPOsRelated Entities
Morgan Stanley, Jefferies & Co, Merrill Lynch, Bank of America
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
